← All trials
NCT04528927
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- Jul 15, 2020
- Completion date
- Jul 15, 2020
- First posted
- Aug 27, 2020
- Last posted
- Aug 27, 2020
- Enrollment
- —
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abderrahmane Mami HospitalLead sponsor
- Abderrahmane Mami HospitalReponsible party - principal investigator
- DatametrixCollaborator
- Eshmoun Clinical Research CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.